COLUMBIA, Md., Jan. 11 /PRNewswire-FirstCall/ -- Martek Biosciences
(Nasdaq: MATK) today announced the election of Polly B. Kawalek to its Board
of Directors.
Mrs. Kawalek previously served for 25 years in various capacities at
Quaker Oats, a $5 billion consumer goods company and a division of PepsiCo.
She was the President of Quaker Foods at the time of her retirement in 2004.
Mrs. Kawalek holds a B.A. from Middlebury College in Middlebury, Vermont,
and a M.B.A. from the University of Chicago Graduate School of Business in
Chicago , IL. She currently serves as a director for Kimball International
(Nasdaq: KBALB) and Elkay Manufacturing Co., a privately held company.
In addition, Martek announced that current directors Gordon S. Macklin and
Dr. Richard J. Radmer have indicated that they will retire from Martek's Board
of Directors after their terms expire in March 2006 . Mr. Macklin has been a
director of Martek since 1998. Dr. Radmer, a founder of Martek, has been a
director of Martek since the Company's inception in 1985 and served as
President of the Company until his retirement from that position in March
2003 .
Martek's Chairman and CEO, Henry 'Pete' Linsert said, 'Gordon Macklin and
Richard Radmer were essential to Martek's growth and success. Their advice
and presence will be missed. I am pleased that Polly Kawalek has joined
Martek's Board. Polly's leadership of Quaker Foods and her experience in the
food industry will be important to the Company's future.'
Martek Biosciences Corporation develops, manufactures and sells naturally
produced products from microalgae and fungi. The Company's products include:
(1) specialty, nutritional oils for infant formula that aid in the development
of the eyes and central nervous system in newborns; (2) nutritional
supplements and food ingredients that may play a beneficial role in promoting
mental and cardiovascular health throughout life; and (3) powerful fluorescent
markers for diagnostics, rapid miniaturized screening, and gene and protein
detection.
CONTACT:
Kyle Stults
Investor Relations
410-740-0081
SOURCE Martek Biosciences Corporation
